Alliance for Clinical Trials in Oncology

02/05/2026

Findings from the CALGB (Alliance) 80702 trial were recently published in JAMA Oncology. This study demonstrates how a ctDNA blood test can guide the use of NSAIDs (celecoxib) after surgery for stage III colon cancer:
✅ Patients with detectable ctDNA (indicating residual disease) experienced significantly improved survival when celecoxib was added after chemotherapy.
✅ Patients without ctDNA did not benefit, helping avoid unnecessary treatment.
🔗 Learn more: https://bit.ly/JAMA-NSAID

02/04/2026

The Alliance is committed to more than discovering new and better ways to treat cancer — we’re equally focused on preventing it.
On this , we’re taking a moment to highlight the essential role of prevention in reducing the risk of cancer before it starts. Prevention isn’t one action — it’s a combination of healthier choices, early detection, community education, and access to resources that empower people to protect their long term health.
From reducing to***co use and limiting exposure to harmful substances, to regular screenings and genetic testing for at-risk groups, prevention strategies have the power to save lives and reduce the burden of cancer across communities. The science is clear: when we invest in prevention, we change the future.
Learn more about our active cancer control trials that are making a real difference at https://bit.ly/Prevent26

02/04/2026

The Alliance is committed to more than discovering new and better ways to treat cancer — we’re equally focused on preventing it.
On this , we’re taking a moment to highlight the essential role of prevention in reducing the risk of cancer before it starts. Prevention isn’t one action — it’s a combination of healthier choices, early detection, community education, and access to resources that empower people to protect their long term health.
From reducing to***co use and limiting exposure to harmful substances, to regular screenings and genetic testing for at-risk groups, prevention strategies have the power to save lives and reduce the burden of cancer across communities. The science is clear: when we invest in prevention, we change the future.
Learn more about our active cancer control trials that are making a real difference at https://bit.ly/Prevent26

Alliance National Clinical Trials Network

02/03/2026

New Clinical Trial Alert: Alliance A232402 CD – The PAGODA Trial, focused on improving care for people with gastrointestinal cancers
This study, led by Gabriel Brooks, MD, MPH, of Dartmouth Geisel School of Medicine, aims to prevent treatment delays, which can significantly impact outcomes for patients. By addressing barriers and streamlining care, the PAGODA Trial seeks to ensure timely and effective treatment for those who need it most.
Learn at https://bit.ly/PAGODA26.

02/02/2026

The trial is now enrolling patients with colorectal cancer that has spread beyond the liver. This study is designed for individuals who:
✅ Responded well to initial chemotherapy
✅ Have up to 4 treatable cancer sites
This trial aims to explore innovative approaches to improve outcomes for patients facing complex metastatic disease.
Learn more and see if you or someone you know may be eligible: https://bit.ly/Alliance-A022101

02/02/2026

🚨 New Findings in Prostate Cancer Symptom Management
A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin significantly reduces hot flashes in men undergoing hormone therapy for prostate cancer. The results from Alliance A222001, led by Bradley Stish, MD, of the Mayo Clinic, were just published in the Journal of Clinical Oncology.
Hot flashes affect up to 80% of men receiving androgen deprivation therapy, often disrupting sleep, energy levels, and quality of life. This study shows that oxybutynin—commonly used for overactive bladder—offers clinically meaningful improvements in both symptom frequency and severity.
Key findings include:
• Both 2.5 mg and 5 mg twice daily doses significantly outperformed placebo
• Improvements were seen as early as the first week
• Up to 79% of participants on the higher dose achieved at least a 50% reduction in hot flash scores
• Treatment was generally well tolerated, with dry mouth as the most common side effect
Learn more at https://bit.ly/Stish-JCO.

01/30/2026

From Sept 2024 to Aug 2025, Alliance investigators published 51 manuscripts—and the quality speaks volumes:
✅ 66% in journals with Impact Factor >5
✅ 6 papers in top-tier journals with IF >40:
• 2 in New England Journal of Medicine (IF 78.5)
• 1 in JAMA (IF 55)
• 1 in Nature Medicine (IF 49.2)
• 2 in Journal of Clinical Oncology (IF 43.4)
This reflects the incredible commitment to advancing cancer research and improving patient care.
📌 See the full list: https://bit.ly/TopJournals

01/29/2026

📢 New Clinical Trial Alert! Jennifer Ligibel, MD (Dana-Farber Cancer Institute) and Kathryn Schmitz, PhD (UPMC Hillman Cancer Center) are leading Alliance A222302, a study exploring the feasibility of a telehealth exercise program for cancer patients. The goal? To help reduce fatigue and disability and improve quality of life. Learn more about the trial here: https://bit.ly/DEFEND-trial

01/28/2026

Results from phase III AFT-38 PATINA trial, show that adding palbociclib to standard maintenance therapy demonstrates significant progression-free survival benefit in HR+, HER2+ advanced breast cancer. Read more The New England Journal of Medicine : https://bit.ly/NEJM-PATINA

01/28/2026

Now enrolling! Recurrent glioblastoma remains one of the most challenging diagnoses in neuro-oncology. Standard options like lomustine offer limited benefit, highlighting the urgent need for novel strategies.
Led study chair Michael Lim, MD, of Stanford University School of Medicine, Alliance A072201 (MODERN) is a phase II/III clinical trial evaluating whether dual immune checkpoint blockade—nivolumab (anti-PD-1) plus relatlimab (anti-LAG-3)—improves outcomes compared to lomustine chemotherapy in patients with recurrent glioblastoma.
Key objectives:
✔ Assess efficacy of combined immunotherapy vs standard chemo
✔ Explore biomarkers and immune signatures for response prediction
This trial could help define the role of immunotherapy in glioblastoma and advance precision medicine approaches in neuro-oncology.
📌 Learn more: https://clinicaltrials.gov/study/NCT06325683

01/27/2026

Trial Tuesday: Advancing Care for Bladder Cancer
Dr. Matt Galsky of Icahn Mouth Sinai leads the Alliance A032103 (MODERN) trial, investigating whether DNA released from tumor cells into the blood can help identify the best immunotherapy treatment after surgery for bladder cancer.
This research could transform how we personalize treatment and improve outcomes for patients by using circulating tumor DNA (found in a common blood test) as a guide for therapy decisions.
📌 Learn more: https://bit.ly/Alliance-A032103

01/27/2026

ThomasHope, MD, of UCSF Hospitals and Deaglan McHugh, MD, of Memorial Sloan Kettering Cancer Center talk to AuntMinnie about Alliance A032304 (RECIPROCAL), a phase III study to optimize targeted radiation therapy to minimize side effects while preserving efficacy in prostate cancer
https://bit.ly/A032304-AM